Stocklytics Platform
Asset logo for symbol PTCT
PTC Therapeutics
PTCT68
$46.24arrow_drop_up2.14%$0.96
High Growth
Asset logo for symbol PTCT
PTCT68

$46.24

arrow_drop_up2.14%

Performance History

Chart placeholder
Key Stats
Open$44.77
Prev. Close$45.25
EPS-5.94
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range44.74
47.26
52 Week Range17.53
54.14
Ratios
EPS-5.94

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About PTC Therapeutics (PTCT)

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of novel medicines for rare disorders. The company's product pipeline includes treatments for diseases such as Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA). PTC Therapeutics' lead product is Translarna, an oral medication for the treatment of DMD caused by a nonsense mutation. The company is also developing other therapies for SMA and rare genetic disorders. PTC Therapeutics is committed to bringing innovative therapies to patients with limited treatment options.
The stock price of PTC Therapeutics Inc (PTCT) has experienced fluctuations over the years. In the past, PTCT stock price has ranged from a low of $5.67 to a high of $66.95. The 52-week range for PTCT is $25.46 to $66.95. It is important to note that stock prices can be influenced by various factors, including market conditions, investor sentiment, and company news.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS
Headquarters
South Plainfield
Employees
1402
Exchange
NASDAQ
add PTC Therapeutics  to watchlist

Keep an eye on PTC Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is PTC Therapeutics 's (PTCT) price per share?

The current price per share for PTC Therapeutics (PTCT) is $46.24. The stock has seen a price change of $0.97 recently, indicating a 2.14% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for PTC Therapeutics (PTCT)?

For PTC Therapeutics (PTCT), the 52-week high is $54.15, which is 17.1% from the current price. The 52-week low is $17.53, the current price is 163.78% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is PTC Therapeutics (PTCT) a growth stock?

PTC Therapeutics (PTCT) has shown an average price growth of -3.95% over the past three years. It has received a score of 65 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying PTC Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is PTC Therapeutics (PTCT) stock price performance year to date (YTD)?

As of the latest data, PTC Therapeutics (PTCT) has a year-to-date price change of 64.91%. Over the past month, the stock has experienced a price change of 10.2%. Over the last three months, the change has been 26.2%. Over the past six months, the figure is 38.9%. Looking at a longer horizon, the five-year price change stands at -4.8%.
help

Is PTC Therapeutics (PTCT) a profitable company?

PTC Therapeutics (PTCT) has a net income of -$626.6M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.02% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -26.41% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $937.82M, with a revenue growth rate of 34.2%, providing insight into the company's sales performance and growth. The gross profit is $872.34M. Operating income is noted at -$349.4M. Furthermore, the EBITDA is $21.85M.
help

What is the market capitalization of PTC Therapeutics (PTCT)?

PTC Therapeutics (PTCT) has a market capitalization of $3.57B. The average daily trading volume is 46.29, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level